1156 / 1578
/
Overview
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
9
1.
General outline
2.
SBRT combined with targeted drugs
3.
SBRT combined with immunotherapy
4.
Safety of SBRT combined with novel drugs
/
Gefitinib
in mutant EGFR
Maemondo NEJM 2010
Crizotinib
in ALK positive
Shaw NEJM 2013
Brahmer NEJM 2015
Nivolumab
in unselected patients
Ø
Substantial and clinically relevant improvement
Ø
Still: 60 – 80% develop PD after 12 months
Rational for combining targeted
drugs & SRT
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
10